These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33980287)

  • 1. Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2).
    Gissen P; Specchio N; Olaye A; Jain M; Butt T; Ghosh W; Ruban-Fell B; Griffiths A; Camp C; Sisic Z; Schwering C; Wibbeler E; Trivisano M; Lee L; Nickel M; Mortensen A; Schulz A
    Orphanet J Rare Dis; 2021 May; 16(1):217. PubMed ID: 33980287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presymptomatic treatment of classic late-infantile neuronal ceroid lipofuscinosis with cerliponase alfa.
    Schaefers J; van der Giessen LJ; Klees C; Jacobs EH; Sieverdink S; Dremmen MHG; Spoor JKH; van der Ploeg AT; van den Hout JMP; Huidekoper HH
    Orphanet J Rare Dis; 2021 May; 16(1):221. PubMed ID: 33990214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).
    Gutić M; Milosavljević MN; Safiye T; Milidrag A; Jankovic SM
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):561-570. PubMed ID: 36994735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
    Estublier B; Cano A; Hoebeke C; Pichard S; Scavarda D; Desguerre I; Auvin S; Chabrol B
    Eur J Paediatr Neurol; 2021 Jan; 30():17-21. PubMed ID: 33348105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series.
    Wibbeler E; Wang R; Reyes EL; Specchio N; Gissen P; Guelbert N; Nickel M; Schwering C; Lehwald L; Trivisano M; Lee L; Amato G; Cohen-Pfeffer J; Shediac R; Leal-Pardinas F; Schulz A
    J Child Neurol; 2021 May; 36(6):468-474. PubMed ID: 33356800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of Intraventricular Cerliponase Alfa for CLN2 Disease.
    Schulz A; Ajayi T; Specchio N; de Los Reyes E; Gissen P; Ballon D; Dyke JP; Cahan H; Slasor P; Jacoby D; Kohlschütter A;
    N Engl J Med; 2018 May; 378(20):1898-1907. PubMed ID: 29688815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment.
    Mortensen A; Raebel EM; Wiseman S
    Orphanet J Rare Dis; 2022 Jan; 17(1):19. PubMed ID: 35045884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics.
    de Los Reyes E; Lehwald L; Augustine EF; Berry-Kravis E; Butler K; Cormier N; Demarest S; Lu S; Madden J; Olaya J; See S; Vierhile A; Wheless JW; Yang A; Cohen-Pfeffer J; Chu D; Leal-Pardinas F; Wang RY
    Pediatr Neurol; 2020 Sep; 110():64-70. PubMed ID: 32684372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Cerliponase Alfa: Recombinant Human Enzyme Replacement Therapy for Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2.
    Lewis G; Morrill AM; Conway-Allen SL; Kim B
    J Child Neurol; 2020 Apr; 35(5):348-353. PubMed ID: 31884868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the retinal function by flash-ERG in one child suffering from neuronal ceroid lipofuscinosis CLN2 treated with cerliponase alpha: case report.
    Rigaudière F; Nasser H; Pichard-Oumlil S; Delouvrier E; Lopez-Hernandez E; Milani P; Auvin S; Delanoë C
    Doc Ophthalmol; 2021 Aug; 143(1):99-106. PubMed ID: 33956290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease.
    Hammon K; de Hart G; Vuillemenot BR; Kennedy D; Musson D; O'Neill CA; Katz ML; Henshaw JW
    Clin Transl Sci; 2021 Sep; 14(5):1810-1821. PubMed ID: 34076336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy.
    Specchio N; Pietrafusa N; Trivisano M
    Ther Clin Risk Manag; 2020; 16():213-222. PubMed ID: 32280231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerliponase Alfa: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(11):1247-1249. PubMed ID: 28589525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
    Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW
    Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in amyotrophic lateral sclerosis using EQ-5D-5L.
    Wei QQ; Hou Y; Chen Y; Ou R; Cao B; Zhang L; Yang T; Shang H
    Health Qual Life Outcomes; 2021 Jul; 19(1):181. PubMed ID: 34284776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group.
    Sampaio LPB; Manreza MLG; Pessoa A; Gurgel-Giannetti J; Coan AC; Júnior HVL; Embiruçu EK; Henriques-Souza AMM; Kok F
    Arq Neuropsiquiatr; 2023 Mar; 81(3):284-295. PubMed ID: 37059438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies.
    Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S
    Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating health state utilities in primary hyperoxaluria type 1: a valuation study.
    de Freitas HM; Danese D; Hubig L; Lloyd A; Lombardelli S
    J Med Econ; 2023; 26(1):386-393. PubMed ID: 36852648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.